SYBLEU (SYBE) 10-Q 16 Oct 23 2024 Q1 Quarterly report Financial data

Cover

Cover	3 Months Ended
	Sep. 30, 2023 shares
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2023
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--06-30
Entity File Number	333-248059
Entity Registrant Name	SYBLEU INC.
Entity Central Index Key	0001818674
Entity Tax Identification Number	85-1412307
Entity Incorporation, State or Country Code	WY
Entity Address, Address Line One	1034 Throggs Neck Expressway
Entity Address, City or Town	Bronx
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10465
City Area Code	(800)
Local Phone Number	807-4631
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding	10,613,492

Condensed Balance Sheets (Unaud

Condensed Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2023	Jun. 30, 2023
CURRENT ASSETS
Cash	$ 132	$ 3,786
Prepaid Expenses	9,319	15,613
Total Current Assets	9,451	19,399
OTHER ASSETS
Investment Securities	423	1,920
Prepaid Expenses ( Long Term)	9,149	9,149
Acquired Intangible Assets, net of amortization	294,680	300,000
Total Other Assets	304,252	311,069
TOTAL ASSETS	313,703	330,468
Current Liabilities:
Income Taxes Payable	10,935	10,935
Notes Payable	183,000	177,500
Expenses Accrued but Unpaid	6,914	15,500
Interest Accrued but Unpaid	39,573	27,476
Total Current Liabilities	240,422	231,411
Long Term Liabilities:
Unearned Income	147,053	150,002
Note Payable	300,000	300,000
Total Liabilities	687,475	681,413
Common Stock ($.0001 par value) 100,000,000 shares authorized; par value $0.0001; 10,613,492 shares issued and outstanding as of September 30, 2023 and 10,613,492 shares issued and outstanding  as of June 30, 2023	1,062	1,062
Additional Paid in capital	179,348	179,348
Common Stock Payable	117,500	0
Contributed Capital	5,311	0
Retained Earnings (Deficit)	(676,993)	(531,355)
Total Stockholders' Equity (Deficit)	(373,772)	(350,945)
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)	$ 313,703	$ 330,468

Condensed Balance Sheets (Una_2

Condensed Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2023	Jun. 30, 2023
Statement of Financial Position [Abstract]
Common Stock, Shares Authorized	100,000,000	100,000,000
Common Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Common Stock, Shares, Outstanding	10,613,492	10,613,492

Condensed Statement of Operatio

Condensed Statement of Operations (Unaudited) - USD ($)	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
REVENUES
License Fees	$ 2,949	$ 2,949
TOTAL REVENUES	2,949	2,949
Research and Development:
Staff Expenses	949	0
Licensing Expenses	2,493	0
Intellectual Property Acquisition Costs	105,000	0
Total Research and Development	108,442	0
General and Administrative:
Transfer Agency Fees	873	641
Other General and Administrative Expenses	5,121	1,029
Total General and Administrative	5,994	1,670
Consulting, Related Party	2,495	0
Consulting:
Accounting	11,000	11,000
Information Technology Consulting	1,742	0
Total Consulting	15,238	11,000
Total Costs and Expenses	129,674	12,670
OPERATING Income( LOSS)	(126,724)	(9,721)
OTHER INCOME AND EXPENSES
Unrealized Gain (Loss) on Investment Securities	(1,498)	(6,539)
Interest Income (Expense)	(12,097)	(3,490)
Amortization of Acquired Intangible Assets	(5,320)	0
TOTAL OTHER INCOME (EXPENSES)	(18,914)	(10,029)
NET INCOME ( LOSS) before taxes	(145,639)	(19,750)
Provision for Income Taxes	0	0
NET INCOME ( LOSS)	$ (145,639)	$ (19,750)
BASIC AND FULLY DILUTED LOSS PER SHARE	$ (0.01)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING	10,613,492	10,418,000

Condensed Statements of Shareho

Condensed Statements of Shareholders Equity (Deficit) (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Contributed Capital [Member]	Common Stock Payable [Member]	Total
Beginning balance, value at Jun. 30, 2021	$ 1,042	$ 100,049	$ (105,705)	$ (4,614)
Beginning balance, shares at Jun. 30, 2021	10,418,000
Net Loss			(132,307)	(132,307)
Ending balance, value at Sep. 30, 2021	$ 1,042	100,049	(238,012)	(136,921)
Ending balance, shares at Sep. 30, 2021	10,418,000
Net Loss			(61,751)	(61,751)
Ending balance, value at Dec. 31, 2021	$ 1,042	100,049	(299,763)	(198,672)
Ending balance, shares at Dec. 31, 2021	10,418,000
Net Loss			(27,030)	(27,030)
Ending balance, value at Mar. 31, 2022	$ 1,042	100,049	(326,793)	(225,702)
Ending balance, shares at Mar. 31, 2022	10,418,000
Beginning balance, value at Jun. 30, 2022	$ 1,042	100,049	(351,051)			$ (249,960)
Beginning balance, shares at Jun. 30, 2022	10,418,000
Net Loss			(19,750)			(19,750)
Ending balance, value at Sep. 30, 2022	$ 1,042	100,049	(370,801)			(269,710)
Ending balance, shares at Sep. 30, 2022	10,418,000
Beginning balance, value at Jun. 30, 2023	$ 1,062	179,348	(531,355)			(350,945)
Beginning balance, shares at Jun. 30, 2023	10,613,492
Net Loss			(145,639)			(145,639)
Capital Contributions during the three months ended September 30, 2023				5,311		5,311
Additions (Subtractions) Common Stock Payable  three months ended September 30, 2023					117,500	117,500
Ending balance, value at Sep. 30, 2023	$ 1,062	$ 179,348	$ (676,993)	$ 5,311	$ 117,500	$ (373,772)
Ending balance, shares at Sep. 30, 2023	10,613,492

Condensed Statement of Cash Flo

Condensed Statement of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Changes in Operating Assets and Liabilities
(Increase) Decrease in Prepaid Expenses	$ 6,294	$ 3,188
Increase (Decrease) in Accrued Expenses	16,012
Increase( Decrease) in Unearned Income	(2,949)	(2,949)
Unrealized Loss (Gain) in Investment Securities	1,498	6,539
Increase in Common Stock Payable	105,000
Increase in Amortization of Acquired Intangible Assets	5,320
Increase in Capital Contributions	5,311
Net Cash provided by (used) in Operating Activities	(9,154)	(12,972)
CASH FLOWS FROM FINANCING ACTIVITIES
Increase (Decrease)   in Notes Payable	5,500
Net Cash provided by (used) in Financing Activities	5,500	0
Net Increase (Decrease) in Cash	(3,654)	(12,972)
Cash at Beginning of Period	3,786	66,850
Cash at End of Period	132	53,878
Supplemental Cash Flow Information:
Interest Paid	0	0
Income Taxes Paid	$ 0	$ 0

ORGANIZATION AND SUMMARY OF SIG

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SYBLEU INC. (“Company”) was organized June 12, 2020 under the laws of the State of Wyoming. T he Company intends to engage primarily in the acquisition, licensing and development of regenerative medical applications up to the point of successful completion of Phase I and or Phase II clinical trials after which the Company would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials. The primary factor to be considered by us in arriving at a decision to advance an application further to Phase III clinical trials would be a greater than anticipated indication of efficacy seen in Phase I trials. A. BASIS OF ACCOUNTING The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a June 30 year-end. B. USE OF ESTIMATES The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. C. CASH EQUIVALENTS The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. D. FAIR VALUE OF FINANCIAL INSTRUMENTS Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value: Level 1: Quoted prices in active markets for identical assets or liabilities Level 2: Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. E. RESEARCH AND DEVELOPMENT COSTS Research and development expenses relate primarily to the cost of discovery and research programs. Research and development costs are charged to expense as incurred. Research and development expenses consist mainly of evaluating potential Contract Research Organizations and filing of a provisional patent application. F. STOCK BASED COMPENSATION Stock issued for Employee Compensation Stock based compensation to employees is accounted for at the award’s fair value at grant, less the amount (if any) paid by the award recipient. During the quarter ended September 30, 2023 no Stock issued for Non-Employee Services Stock Based compensation to non-employees is accounted for in accordance with ASC 505-50. ASC 505-50 requires entities to account for non-employee equity transactions based on either the fair value of the services received or the fair value of the equity instrument issued utilizing whichever measurement is most reliable During the quarter ended December 31, 2022 no Pursuant to ASC 505-50-30-11505-50-30-11 an issuer shall measure the fair value of the equity instruments in these transactions using the stock price and other measurement assumptions as of the earlier of the following dates, referred to as the measurement date: i. The date at which a commitment for performance by the counterparty to earn the equity instruments is reached (a performance commitment); and ii. The date at which the counterparty’s performance is complete. G. INCOME TAXES The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date. The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of June 30, 2023 the Company had no The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of 100% has been established. Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19. H. BASIC EARNINGS (LOSS) PER SHARE The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, "Earnings Per Share", which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception. Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding. There were no Common Stock Equivalents as of June 30, 2023. I. INTANGIBLE ASSETS The Company amortizes its intangible assets with definite useful lives over their estimated useful lives and reviews these assets for impairment. The Company’s acquired intangible assets with definite useful lives consists of a 50% interest in and to including, but not limited to, the copyrights, trade secrets, trademarks and associated good will and patent rights to (a) the intellectual property disclosed in US Patent US11377442B2 (Small molecule agonists and antagonists of NR2F6 activity) and (b) ) the intellectual property disclosed in US Patent US US10472351B2 (Small molecule agonists and antagonists of NR2F6 activity in animals).

RECENT ACCOUNTING PRONOUNCEMENT

RECENT ACCOUNTING PRONOUNCEMENTS	3 Months Ended
	Sep. 30, 2023
Accounting Changes and Error Corrections [Abstract]
RECENT ACCOUNTING PRONOUNCEMENTS	NOTE 2 RECENT ACCOUNTING PRONOUNCEMENTS The Company has adopted Accounting Standards Update 2014-09, Revenue from Contracts with Customers (Topic 606). The guidance in this Update supersedes the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific guidance throughout the Industry Topics of the Codification. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. The Company has adopted the provisions of this ASU effective the fiscal year ended 2020. This guidance did not have a material impact on the Company’s Financial Statements. On February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842). The ASU requires organizations that lease assets, referred to as “lessees,” to recognize on the consolidated statement of financial position the rights and obligations created by those leases. The ASU also requires disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. These disclosures include qualitative and quantitative requirements, providing additional information about the amounts recorded in the consolidated financial statements. The ASU on leases became effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. This guidance is not expected to have a material impact on the Company’s financial statements. In June 2018, the FASB issued ASU No. 2018-07, Compensation - Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting.

GOING CONCERN

GOING CONCERN	3 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	NOTE 3. GOING CONCERN The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has generated net losses of $ 676,933 Management plans to raise additional funds by offering securities for cash. Management has yet to decide what type of offering the Company will use or how much capital the Company will raise. There is no guarantee that the Company will be able to raise any capital through any type of offerings.

RELATED PARTY TRANSACTIONS.

RELATED PARTY TRANSACTIONS.	3 Months Ended
	Sep. 30, 2023
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS.	NOTE 4. RELATED PARTY TRANSACTIONS. The Company utilizes approximately 500 square feet of office space at 1034 Throggs Neck Expressway, Bronx NY 10465 provided to the Company by Joseph G. Vaini, the Company’s sole officer and director, on a month to month basis free of charge. The property is utilized as office space. We believe that the foregoing properties are adequate to meet our current needs for office space. On January 8, 2023 the Company entered into an agreement with Joanne Vaini whereby Joanne Vaini agreed to provide bookkeeping services for the Company for the period beginning January 9, 2023 and ending July 9, 2024 (“Agreement”) for total consideration consisting of $ 15,000 . Joanne Vaini is the spouse of Joseph G. Vaini the Company’s sole officer and director. On June 26, 2023 the Company was granted an exclusive worldwide license by DYO Biotechnologies, Pty, Ltd (“DYO”) to (a) to make, have made, use, offer for sale, sell, perform, have performed export and import Licensed Products and Licensed Services; (b) to practice Licensed Methods; and (c) to use Technology, all in the Field, within the Territory and during the Term (the “License”). “Technology” is defined in the License as” Artificial intelligence/machine learning engine designed to utilize existing chemical library structures in an integrated model to predict highly specific and sensitive novel chemical structures for molecular targets.” “Licensed Services” are defined in the License as “any service performed by Company or Sublicensee for the benefit of a third party that, in whole or in part, (a) uses Technology; (b) uses Licensed Product(s); or (c) that practices or is enabled by a Licensed Method.” “Licensed Method” is defined in the License as “any method or process that uses Technology” “Field” is defined in the License as small molecule drug development and commercialization for human and/or animal health. “Territory” is defined in the License as “worldwide”. The Term of the License is the period of time beginning on the effective date of this Agreement which shall be June 26, 2023 and terminating on the last to expire Royalty Term. “Royalty Term” is defined in the License as that period of time beginning on the first commercial sale of a Licensed Product in a given country and, expires on a country-by-country basis with respect to each Licensed Product, upon the later of: (a) the expiration, abandonment, or invalidation of the last to expire, abandoned or invalidated Valid Claim of the Patent Rights in such country; (b) the expiration of any granted statutory period of marketing exclusivity within a country; and (c) 12 years from of the date of the first commercial sale of such Licensed Product in such country. Pursuant to the terms and conditions of the License the Company shall raise $2,000,000 US through either debt or equity financing within 2 years of execution of this Agreement (“Funding”). The Company shall enter into a research collaboration agreement with DYO upon mutually acceptable terms and conditions within 30 days of Funding (“Research Agreement). Substantially all of the Funding shall be utilized to enable the Technology for the benefit of developing Company’s existing and future small molecule drug intellectual property. It is anticipated that this research agreement will utilize substantially all of these funds over two years. It is agreed that the Company shall exclusively possess all right, title and interest in and to including, but not limited to, the copyrights, trade secrets, trademarks and associated good will and patent rights to any and all inventions, discoveries, intellectual property and chemical structures resulting from this Research Agreement. Pursuant to the terms and conditions of the License the Company shall pay to DYO a Royalty equal to five percent (5%) of the Net Sales ( as such term is defined in the License) of any Licensed Method, Service or Product per annum. The License also imposes an obligation upon the Company to make minimum royalty payments to DYO over the course of the Term. Pursuant to the terms and conditions of the License the l Company paid to DYO 309,000 25,000 DYO shall not, directly or indirectly, offer, issue, sell, contract to sell (including without limitation short sale), grant any option for the sale of, pledge or otherwise dispose of or transfer any or all of the Stock Payment for a period of two years from the date of issuance. Pursuant to the terms and conditions of the License Upon the occurrence of each of the following events (each a “Milestone”)), the Company shall make a cash payment (“Milestone Payment”) in the amount corresponding to such Milestone within thirty days after achievement of each Milestone: Milestone AMOUNT 1. Dosing of a first human patient in a Phase I or Phase I/II Clinical Trial for Licensed Product $150,000 US 2. Dosing of a first patient in a Phase III Clinical Trial for Licensed Product $500,000 US 3. FDA (US) Approval of a Licensed Product $3,000,000 US 4. EMA (EU) Approval of a Licensed Product $1,500,000 US 5. PMDA (JPN) Approval of a Licensed Product $1,000,000 US 6. Cumulative Net Sales of Licensed Products reach $100 Million $2,000,000 US This License may be terminated by DYO in the event: No licensed Method, Service or Product has been granted Patent Protection in at least one jurisdiction after the expiration of four years from execution The sum of $2,000,000 shall not have been raised within 2 years of execution of the license The Research Agreement shall not have been entered into as of thirty days subsequent to the Funding. The Company shall not have achieved cumulative Net Sales of Licensed Product, Service and Methods of at least $10,000,000 as of a date that is ten years from the execution of the license The Company shall fail to pay any consideration required under the license and such failure remains uncured for thirty days. This License may be terminated by the Company in the event: DYO shall be determined to not have exclusive unencumbered Patent Rights to the Technology in whole or in part. Any other entity shall be determined to have the right- exercised or not- to utilize the Technology ( in whole or in part) to develop make, use, offer for sale, sell, perform, have performed export and import and sell products, methods and services which can reasonably be expected to be similar to or competitive with products, methods and services to be developed by the Company utilizing the rights granted by the License. . DYO shall have failed to demonstrate during the course of due diligence to the satisfaction of the Company that the Technology can be effectively utilized for the purposes intended by this License In the event that the Agreement is terminated pursuant to the any of the abovementioned the Stock Payment shall be promptly returned by DYO to the Company for cancellation. Dr. Harry Lander serves as Chief Scientific Officer of the Company and is a shareholder of the Company. Dr. Harry Lander also serves as Managing Director of DYO and is a controlling shareholder of DYO. On July 14, 2023 the Company’s Chief Executive Officer made a $ 3,600 On August 17, 2023 the Company’s Chief Executive Officer made a $ 311 On August 30, 2023 the Company’s Chief Executive Officer made a $ 150 On September 5, 2023 the Company’s Chief Executive Officer made a $ 1,000 On September 29, 2023 the Company’s Chief Executive Officer made a $ 250

NOTES PAYABLE

NOTES PAYABLE	3 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
NOTES PAYABLE	NOTES PAYABLE Schedule of related party debt Bostonia Partners $ 140,000 Zander Therapeutics Inc. $ 18,000 Zander Biologics, Inc. $ 300,000 Notes Payable, as of September 30, 2023 $ 486,000 $ 10,000 10 September 20, 2022 $ 30,000 10 September 30, 2022 $ 100,000 owed by the Company to Bostonia Partners bears simple interest at 10 % and is due and payable October 5, 2022 . $ 12,500 10 April 4, 2024 $ 25,000 10 June 29, 2024 $ 300,000 10 June 30, 2025 $ 5,500 10 August 2, 2024

INVESTMENT SECURITIES

INVESTMENT SECURITIES	3 Months Ended
	Sep. 30, 2023
Schedule of Investments [Abstract]
INVESTMENT SECURITIES	NOTE 6. INVESTMENT SECURITIES On March 11, 2021 the Company was paid 6,500 On September 30, 2023 the Company revalued 6,500 As of September 30, 2023: Schedule Of Common Shares 6,500 Common Shares of Oncology Pharma, Inc. Basis Fair Value Total Unrealized Losses Net Unrealized Gain or (Loss) during the quarter ended September 30, 2023 $ 177,450 $ 423 $ (177,027 ) $ (1,498 )

STOCKHOLDERS_ EQUITY

STOCKHOLDERS’ EQUITY	3 Months Ended
	Sep. 30, 2023
Equity [Abstract]
STOCKHOLDERS’ EQUITY	NOTE 7. STOCKHOLDERS’ EQUITY The stockholders’ equity section of the Company contains the following class of capital stock as of September 30, 2023: Common stock, $ 0.0001 100,000,000 10,613,492 With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Common Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Common Stock owned by such holder times one (1). On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Common Stock shall receive, out of assets legally available for distribution to the Company’s stockholders, a ratable share in the assets of the Corporation.

ORGANIZATION AND SUMMARY OF S_2

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF ACCOUNTING	A. BASIS OF ACCOUNTING The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a June 30 year-end.
USE OF ESTIMATES	B. USE OF ESTIMATES The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
CASH EQUIVALENTS	C. CASH EQUIVALENTS The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.
FAIR VALUE OF FINANCIAL INSTRUMENTS	D. FAIR VALUE OF FINANCIAL INSTRUMENTS Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value: Level 1: Quoted prices in active markets for identical assets or liabilities Level 2: Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
RESEARCH AND DEVELOPMENT COSTS	E. RESEARCH AND DEVELOPMENT COSTS Research and development expenses relate primarily to the cost of discovery and research programs. Research and development costs are charged to expense as incurred. Research and development expenses consist mainly of evaluating potential Contract Research Organizations and filing of a provisional patent application.
STOCK BASED COMPENSATION	F. STOCK BASED COMPENSATION Stock issued for Employee Compensation Stock based compensation to employees is accounted for at the award’s fair value at grant, less the amount (if any) paid by the award recipient. During the quarter ended September 30, 2023 no Stock issued for Non-Employee Services Stock Based compensation to non-employees is accounted for in accordance with ASC 505-50. ASC 505-50 requires entities to account for non-employee equity transactions based on either the fair value of the services received or the fair value of the equity instrument issued utilizing whichever measurement is most reliable During the quarter ended December 31, 2022 no Pursuant to ASC 505-50-30-11505-50-30-11 an issuer shall measure the fair value of the equity instruments in these transactions using the stock price and other measurement assumptions as of the earlier of the following dates, referred to as the measurement date: i. The date at which a commitment for performance by the counterparty to earn the equity instruments is reached (a performance commitment); and ii. The date at which the counterparty’s performance is complete.
INCOME TAXES	G. INCOME TAXES The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date. The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of June 30, 2023 the Company had no The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of 100% has been established. Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.
BASIC EARNINGS (LOSS) PER SHARE	H. BASIC EARNINGS (LOSS) PER SHARE The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, "Earnings Per Share", which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception. Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding. There were no Common Stock Equivalents as of June 30, 2023.
INTANGIBLE ASSETS	I. INTANGIBLE ASSETS The Company amortizes its intangible assets with definite useful lives over their estimated useful lives and reviews these assets for impairment. The Company’s acquired intangible assets with definite useful lives consists of a 50% interest in and to including, but not limited to, the copyrights, trade secrets, trademarks and associated good will and patent rights to (a) the intellectual property disclosed in US Patent US11377442B2 (Small molecule agonists and antagonists of NR2F6 activity) and (b) ) the intellectual property disclosed in US Patent US US10472351B2 (Small molecule agonists and antagonists of NR2F6 activity in animals).

NOTES PAYABLE (Tables)

NOTES PAYABLE (Tables)	3 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Schedule of related party debt	Schedule of related party debt Bostonia Partners $ 140,000 Zander Therapeutics Inc. $ 18,000 Zander Biologics, Inc. $ 300,000 Notes Payable, as of September 30, 2023 $ 486,000

INVESTMENT SECURITIES (Tables)

INVESTMENT SECURITIES (Tables)	3 Months Ended
	Sep. 30, 2023
Schedule of Investments [Abstract]
Schedule Of Common Shares	Schedule Of Common Shares 6,500 Common Shares of Oncology Pharma, Inc. Basis Fair Value Total Unrealized Losses Net Unrealized Gain or (Loss) during the quarter ended September 30, 2023 $ 177,450 $ 423 $ (177,027 ) $ (1,498 )

ORGANIZATION AND SUMMARY OF S_3

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)	3 Months Ended
	Sep. 30, 2023 USD ($) shares
Defined Benefit Plan Disclosure [Line Items]
Uncertain tax positions | $	$ 0
Employee [Member]
Defined Benefit Plan Disclosure [Line Items]
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture	0
Non Employee [Member]
Defined Benefit Plan Disclosure [Line Items]
Number of shares issued for services	0

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative)	40 Months Ended
	Sep. 30, 2023 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net income loss	$ 676,933

RELATED PARTY TRANSACTIONS. (De

RELATED PARTY TRANSACTIONS. (Details Narrative) - USD ($)		3 Months Ended
	Jan. 08, 2023	Sep. 30, 2023	Jun. 30, 2023	Sep. 30, 2022	Sep. 06, 2023	Sep. 01, 2023	Aug. 18, 2023	Jul. 15, 2023
Related Party Transaction [Line Items]
[custom:StockIssuedDuringPeriodSharesIssuedForConsideration]			309,000
[custom:LicenseFees]		$ 2,949	$ 25,000	$ 2,949
[custom:CapitalContribution-0]		$ 250			$ 1,000	$ 150	$ 311	$ 3,600
Joanne Vaini [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Amounts of Transaction	$ 15,000

NOTES PAYABLE (Details)

NOTES PAYABLE (Details)	Sep. 30, 2023 USD ($)
Defined Benefit Plan Disclosure [Line Items]
Notes payable, related parties	$ 486,000
Bostonia Partners [Member]
Defined Benefit Plan Disclosure [Line Items]
Notes payable, related parties	140,000
Zander Therapeutics Inc [Member]
Defined Benefit Plan Disclosure [Line Items]
Notes payable, related parties	18,000
Zander Biologics Inc [Member]
Defined Benefit Plan Disclosure [Line Items]
Notes payable, related parties	$ 300,000

NOTES PAYABLE (Details Narrativ

NOTES PAYABLE (Details Narrative)	3 Months Ended
	Sep. 30, 2023 USD ($)
Bostonia Partners 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Notes payable related parties	$ 10,000
Interest rate	10%
Maturity date	Sep. 20, 2022
Bostonia Partners 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Notes payable related parties	$ 30,000
Interest rate	10%
Maturity date	Sep. 30, 2022
Bostonia Partners 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Notes payable related parties	$ 100,000
Interest rate	10%
Maturity date	Oct. 05, 2022
Zander Therapeutics Inc 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Notes payable related parties	$ 12,500
Interest rate	10%
Maturity date	Apr. 04, 2024
Bostonia Partners 4 [Member]
Defined Benefit Plan Disclosure [Line Items]
Notes payable related parties	$ 25,000
Interest rate	10%
Maturity date	Jun. 29, 2024
Zander Biologics Inc 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Notes payable related parties	$ 300,000
Interest rate	10%
Maturity date	Jun. 30, 2025
Zander Therapeutics Inc 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Notes payable related parties	$ 5,500
Interest rate	10%
Maturity date	Aug. 02, 2024

INVESTMENT SECURITIES (Details)

INVESTMENT SECURITIES (Details) - Oncology Pharma Inc [Member]	3 Months Ended
	Sep. 30, 2023 USD ($)
Schedule of Investments [Line Items]
Investment securities, basis	$ 177,450
Investment securities, fair value	423
Investment securities, total unrealized losses	(177,027)
Investment securities, net unrealized gain or loss realized	$ (1,498)

INVESTMENT SECURITIES (Details

INVESTMENT SECURITIES (Details Narrative) - shares		3 Months Ended
	Mar. 11, 2021	Sep. 30, 2023
Oncology Pharma Inc [Member]
Schedule of Investments [Line Items]
Number of shares issued for property dividend	6,500	6,500

STOCKHOLDERS_ EQUITY (Details N

STOCKHOLDERS’ EQUITY (Details Narrative) - $ / shares	Sep. 30, 2023	Jun. 30, 2023
Equity [Abstract]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	10,613,492
Common stock, shares outstanding	10,613,492	10,613,492